Literature DB >> 851159

Upper genital tract changes associated with exposure in utero to diethylstilbestrol.

R H Kaufman, G L Binder, P M Gray, E Adam.   

Abstract

Hysterosalpingograms of 60 young women exposed in utero to diethystilbestrol were obtained. In 46 instances, documentation of this exposure was obtained from the mother's chart review or confirmed by the attending physician. In 14 instances, the patients' mothers were sure they had received stilbestrol, but documentation could not be specifically confirmed. Hysterosalpingograms of 23 women being investigated for infertility during the same period that the current study was conducted were also reviewed. In 40 women exposed to stilbestrol, changes in the uterus which differed significantly from those seen in the past in nonexposed individuals were noted. These changes consisted of a 'T-shaped appearance of the uterus,' constricting bands in the uterine cavity, a hypoplastic uterus, and less frequently, intrauterine polypoid defects, synechiae, and in one instance a unicornuate uterus. In 36 of the 40 women gross defects were also noted in the cervix. By comparison, in none of the control subjects were defects noted which could be considered comparable with those seen in the DES-exposed patient.

Entities:  

Keywords:  Biology; Clinical Research; Contraceptive Agents, Estrogen; Diethylstilbestrol--side effects; Endocrine System; Endometrial Effects; Endometrium; Estrogens; Examinations And Diagnoses; Genitalia; Genitalia, Female; Hormones; Hysterosalpingography; Physical Examinations And Diagnoses; Physiology; Pregnancy; Reproduction; Research Methodology; Urogenital System; Uterine Effects; Uterus

Mesh:

Substances:

Year:  1977        PMID: 851159     DOI: 10.1016/0002-9378(77)90294-0

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  17 in total

Review 1.  The development of cervical and vaginal adenosis as a result of diethylstilbestrol exposure in utero.

Authors:  Monica M Laronda; Kenji Unno; Lindsey M Butler; Takeshi Kurita
Journal:  Differentiation       Date:  2012-06-06       Impact factor: 3.880

2.  Fetal exposure to DES results in de-regulation of Wnt7a during uterine morphogenesis.

Authors:  C Miller; K Degenhardt; D A Sassoon
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

3.  The effects of medication during pregnancy.

Authors:  J Parboosingh
Journal:  Can Fam Physician       Date:  1981-06       Impact factor: 3.275

Review 4.  Implication of environmental estrogens on breast cancer treatment and progression.

Authors:  Thomas L Gonzalez; James M Rae; Justin A Colacino
Journal:  Toxicology       Date:  2019-03-30       Impact factor: 4.221

5.  Diethylstilbestrol: risks of malignant disease and congenital malformations.

Authors:  R A Kinch
Journal:  Can Med Assoc J       Date:  1979-06-23       Impact factor: 8.262

6.  Symposium on Adolescent Gynecology and Endocrinology. Part II: Secondary amenorrhea, hirsutism in adolescents and the clinical consequences of stilbestrol exposure in utero. The clinical consequences of stilbestrol exposure in utero.

Authors:  R J Kurman
Journal:  West J Med       Date:  1979-12

7.  Paraovarian cysts associated with prenatal diethylstilbestrol exposure. Comparison of the human with a mouse model.

Authors:  A F Haney; R R Newbold; B F Fetter; J A McLachlan
Journal:  Am J Pathol       Date:  1986-09       Impact factor: 4.307

8.  Urinary bisphenol A concentrations and ovarian response among women undergoing IVF.

Authors:  E Mok-Lin; S Ehrlich; P L Williams; J Petrozza; D L Wright; A M Calafat; X Ye; R Hauser
Journal:  Int J Androl       Date:  2009-11-30

9.  Abnormalities in the reproductive system of aged mice after neonatal estradiol exposure.

Authors:  T Mori
Journal:  J Endocrinol Invest       Date:  1986-10       Impact factor: 4.256

10.  Early-life factors and endometriosis risk.

Authors:  Kristen Upson; Sheela Sathyanarayana; Delia Scholes; Victoria L Holt
Journal:  Fertil Steril       Date:  2015-07-26       Impact factor: 7.329

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.